| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b603ecd95b3b1497ae9f30752a676c0e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6afbd19f560437f5d406b637c676c322 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-57 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6845
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-241 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
2017-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec6c64326ea6242ef19469a694c62fbe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be09d0125fb3fe8fcf88f09bcc884c1e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8bfed2c147d66c40ca4550f16088bbae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f4e000776e55401915cc92b52b8fd99
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6eef3f9beda77e1dc651c2d68ca442bb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27151769f48a34bbaf74ea300cd03fab |
| publicationDate |
2018-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3407911-A1 |
| titleOfInvention |
Methods and pharmaceutical composition for the treatment of cancer |
| abstract |
The present invention relates to methods and pharmaceutical composition for the treatment of cancer. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen for cancer, the method comprising: administering a pharmaceutically effective amount of a TNFα blocking agent to a subject in combination with the immune checkpoint inhibitor. |
| priorityDate |
2016-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |